Delivery Order SPE2DB22D1106-SPE2DB25FFCT6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,913.51 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) with an ultimate completion date of August 12, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,191.81 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a direct fulfillment of pharmaceutical supply needs for federal medical procurement. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $3,012.98 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on September 11, 2025, with completion anticipated by September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $14,182.44 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xeljanz 5 mg tablets in quantities of 60 units, with a ceiling value of $6,416.32. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 5, 2025, and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order does not include a set-aside designation and represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $22,621.69 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,952.81 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-unit packaging) with a completion date of June 9, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a direct procurement of pharmaceutical products to support federal healthcare requirements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $18,065.90 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running...
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- The Defense Logistics Agency awarded a $28.8K delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xeljanz 5 mg on September 15, 2025, with completion scheduled for September 16, 2025. This is a firm fixed-price contract with no set-aside designation, meaning it was competitively awarded to the vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCT6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,059.18 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, PA. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime vendor agreement enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including critical medications, vaccines, and specialized medical commodities. The delivery order for Xeljanz, a prescription immunosuppressant medication, reflects the company's role in fulfilling federal medical procurement requirements across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 8/12/25 |